Hepatitis C Drugs Market Health Improvement Aspects, Expert Reviews, Research 2018 to 2026

Hepatitis C Drugs Market Health Improvement
Aspects, Expert Reviews, Research 2018 to 2026
Hepatitis C Drugs Market - By Drug Class (Hepatitis C Virus Protease Inhibitors
(Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, and Voxilaprevir),
Nucleoside/tide Polymerase Inhibitors (Sofosbuvir), NS5A Inhibitors
(Daclatasvir, Elbasvir, Ledipasvir, Pibrentasvir, Velpatasvir, and Ombitasvir),
Non-Nucleoside Polymerase Inhibitors (Dasabuvir), Interferon, and
Combinational drug), and By Distribution Channels (Hospital Pharmacies, Retail
Pharmacies, and Online Pharmacies) - Global Industry Insights, Trends, Outlook,
and Opportunity Analysis, 2018-2026
Hepatitis C virus is a blood-borne virus that infects liver cells, resulting in illness that ranges from mild
and transient effects such as easy bleeding, fatigue, yellow discoloration of skin and eyes, and others to
chronic and serious life-threatening conditions such as liver cirrhosis, liver cancer or liver failure.
Hepatitis C virus is transmitted through needlestick injuries, organ transplant from a carrier, sexually or
from infected mother to fetus. Globally, hepatitis C virus exists in six distinct forms based on its
genotypes amongst which Type 1 is the most common form representing around 60 -70 per cent of
global infections. Click To Read More On Hepatitis C Drugs Market.
Hepatitis C is diagnosed by blood tests for estimating viral load and genotyping, and liver damage tests
such as magnetic resonance elastography (MRE), transient elastography, and liver biopsy. Antiviral
drugs, which inhibits protease or polymerase enzyme of virus is one of the treatments available for
infection caused due to hepatitis C. Currently, no vaccines are available for the prevention of hepatitis
C virus and this provides scope for the market players to expand their company portfolio.
Hepatitis C drug market Driver
According to the World Health Organization (WHO), in 2017, around 71 million people were infected
by chronic hepatitis C worldwide. Furthermore, WHO considers Eastern Mediterranean and European
regions to be the most affected regions with the prevalence rate of 2.3% and 1.5% respectively.
According to the Centers for Disease Control and Prevention, around 2.7 million to 3.9 million people
in the U.S. suffer from hepatitis C. This increasing prevalence of hepatitis C will drive growth of
hepatitis C drug market. Furthermore, this blood- borne virus is easily transmitted by sharing injection
equipment, transfusion of infectious blood, sexually or from infected mother to infant, which will
further propel growth of hepatitis C drug market.
Get PDF Brochure of This Report @ https://www.coherentmarketinsights.com/insight/requestpdf/1489
The governmental initiatives for patients to receive expanded drug coverage is also expected to drive
growth of the market. For instance, in 2018, the Ministry of Health and Long-Term Care of Ontario
announced that all patients are eligible for Ontario Drug Benefit (ODP) irrespective of severity of their
disease. In the same year, Thunder Bay group, HIV / AIDS / hepatitis C education and support services
provider, expanded its access to medicines, as a result of successful negotiations between the provinces
and drug manufacturers.
Hepatitis C Drug Market
The major players in hepatitis C drug market include Merck & Co. Inc., Vertex Pharmaceuticals,
Roche, Gilead Sciences Inc., AbbVie Inc., Johnson & Johnson, and Bristol-Myers Squibb.
There are significant number of drugs available for Hepatitis C over the past few years and is expected
to increase over the forecast period due to large number of drugs in pipeline. Hepatitis C drug market is
revolutionized by direct acting antivirals (DAAs), which aid in the development of highly effective,
INF-free hepatitis C drug regimen in contrast to standard treatment. The pipeline consists of dual as
well as triple DDA combinational therapy against hepatitis C virus. A combination of drugs is more
effective for the treatment of hepatitis C as compared to single regimen.
Ask For Sample Copy of This Business Report @
https://www.coherentmarketinsights.com/insight/request-sample/1489
For instance, in 2016, Gilead submitted a new drug application to the U.S. FDA for the fixed-dose
combination SOF/VEL/voxilaprevir for treatment of HCV genotypes 1–6. Moreover, in January 2017,
EMA granted assessment of SOF/VEL/voxilaprevir combination. Furthermore, in 2017, the U.S. FDA
approved AbbVie’s Mavyret, a combination of glecaprevir and pibrentasvir for the treatment of
hepatitis C. Hepatitis C drug market is hindered due to high medication cost and denial for Medicaid
patients.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]

Hepatitis C virus is a blood-borne virus that infects liver cells, resulting in illness that ranges from mild and transient effects such as easy bleeding, fatigue, yellow discoloration of skin and eyes, and others to chronic and serious life-threatening conditions such as liver cirrhosis, liver cancer or liver failure.

Download Report